Zeus公司任命新CEO - Zeus公司任命Padraic "Paddy" O'Brien为新CEO，标志着公司在EQT所有权下迎来新的增长时期[1] - O'Brien目前担任BD周边干预全球总裁，专注于为患者和医疗服务提供商推进临床治疗的医疗技术公司[2] - O'Brien拥有圣克拉拉大学综合科学学士学位[4] EQT私募股权团队评价 - EQT私募股权咨询团队合伙人Ethan Waxman表示，Paddy的领域知识和经验使他非常适合领导公司迎接下一个增长阶段[5] Zeus公司背景介绍 - Zeus总部位于南卡罗来纳州奥兰治堡，是全球领先的聚合物挤出和导管设计制造商，拥有55年经验，致力于为医疗、航空航天、能源、汽车、光纤等领先行业提供解决方案[6]

Results Show Clinical Workflow, Operational Efficiency and Financial Improvements When Using Automated Dispensing Cabinets FRANKLIN LAKES, N.J., March 13, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new data from a research study evaluating the impact of deploying automated dispensing cabinets in long-term care facilities and an off-site, long-term care pharmacy. Over a 90-day period in the long-term care facilities, me ...

Becton, Dickinson and Company (BDX) , popularly known as BD, is well-poised for growth in the coming quarters, courtesy of its series of product launches over the past few months. The optimism led by a solid first-quarter fiscal 2024 performance and a few strategic deals are expected to contribute further. However, macroeconomic concerns and stiff competition persist.Over the past year, this Zacks Rank #3 (Hold) stock has gained 3.5% compared with the 18.1% rise of the industry and 32.9% growth of the S&P 5 ...

Becton, Dickinson and Company (BDX) , popularly known as BD, recently announced the enrollment of the first patient in the investigational device exemption (IDE) study, AGILITY, which aims to evaluate the efficacy and safety of the BD Vascular Covered Stent in treating peripheral arterial disease (PAD).The first patient in the AGILITY study was enrolled at Trinity Medical Center in Bettendorf, Iowa, by Dr. Nicolas Shammas, Interventional Cardiologist, Cardiovascular Medicine, PLLC.Price PerformanceFor the p ...

股票购买建议 - 有些股票虽然跌至52周低点，但并不意味着就是买入的时机[1] - 需要谨慎选择，避免购买那些便宜的股票，因为它们可能存在业务问题[2] - 有三只股票在52周低点时值得购买，只需稍加整理和关注即可获得可观回报[3]

First Patient Enrollment in AGILITY Study Begins Investigations of Safety and Effectiveness of BD Vascular Covered Stent for Treatment of PADFRANKLIN LAKES, N.J., March 4, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the enrollment of the first patient in the investigational device exemption (IDE) study, "AGILITY," which will assess the safety and effectiveness of the BD Vascular Covered Stent for the treatment of Periphera ...

BDX公司表现 - BDX公司在2024财年第一季度中国市场表现疲软，同比下降5.3%，市场占比仅为6.4%[1] - Alaris泵召回导致BDX公司收入和市场份额下降，但预计Alaris泵在2024财年将逐渐恢复市场份额并产生至少2亿美元的收入[5] 预期展望 - BDX公司预计2024财年有望实现5.5%-6.25%的有机收入增长和50个基点的利润率扩张[8]

联邦储备局和AI科技 - 联邦储备局可能会降低利率，推动股市[1] - AI技术的崛起推动科技股上涨[1] 投资市场趋势 - 高估值使得当前市场对投资资本的投放变得困难[2] - 长期投资者仍有很多好的投资机会[2] 优质投资目标 - 选择具有连续25年以上增加股息支付的公司作为投资目标[3] Emerson Electric (NYSE:EMR) - Emerson Electric (NYSE:EMR)是一家工业公司，现在主要专注于工业自动化领域[4] - Emerson Electric (NYSE:EMR)的股票估值相对较低，是长期投资者的不错选择[6] Exxon Mobil (NYSE:XOM) - Exxon Mobil (NYSE:XOM)是一个稳健的蓝筹股，投资者可以通过它参与下一代能源技术[9] - Exxon Mobil (NYSE:XOM)收购了Denbury Resources，成为美国最大的二氧化碳管道所有者[10] IBM (NYSE:IBM) - IBM (NYSE:IBM)在硬件解决方案领域长期占据主导地位，但错过了现代科技解决方案的发展[11] - IBM (NYSE:IBM)持续投资研发，特别是在人工智能和量子计算领域[13] Becton Dickinson (NYSE:BDX) - Becton Dickinson (NYSE:BDX)是一家领先的医疗器械公司，股票估值相对较低[19] - Becton Dickinson (NYSE:BDX)的股票被认为目前处于深度折扣状态，有投资潜力[20] 3M (NYSE:MMM) - 3M (NYSE:MMM)是一家美国制造业巨头，股票估值相对较低，提供丰厚的股息收益[23] NextEra Energy (NYSE:NEE) - NextEra Energy (NYSE:NEE)是美国领先的可再生能源开发商，股票估值被认为处于低点[27] Sherwin-Williams (NYSE:SHW) - Sherwin-Williams (NYSE:SHW)是美国领先的涂料供应商，利用其市场份额和专业涂装商的领先地位赚取高额利润[31]

FRANKLIN LAKES, N.J., Feb. 27, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Dave Hickey has informed the company of his intent to retire from BD, effective July 1. Hickey is currently executive vice president and president of the Life Sciences segment for BD, a position he has held since January 2021. Prior to his current role, Hickey was president of Integrated Diagnostic Solutions from 2019 to 2021, and president of ...

Becton, Dickinson and Company (BDX) , popularly known as BD and Camtech Health, recently announced their strategic collaboration to uplift cervical cancer screening for women in Singapore by providing them the first-ever option to self-collect a sample amidst the privacy of their own home.The partnership is intended to raise the percentage of cervical cancer screening in Singapore, where the present screening rate is less than half of eligible women.Price PerformanceFor the past six months, BDX’s shares hav ...